Cost-effectiveness of linezolid versus vancomycin in mechanical ventilation-associated nosocomial pneumonia caused by methicillin-resistant staphylococcus aureus

Machado, Alice Beatriz Mombach Pinheiro; Arns, Clovis da Cunha; Follador, Wilson; Guerra, Aline Landre

doi:10.1590/s1413-86702005000300001

Cited by 26 publications

(19 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Commonly reported outcomes include length of hospital stay, quality‐adjusted life‐years, drug costs, costs per episode of infection, and total hospital costs. In these studies, the higher acquisition cost of linezolid was found to be offset by improved survival and, in some cases, a reduction in total healthcare costs; hence linezolid was found to be a cost‐effective alternative to vancomycin .…”

Section: Clinical Management Of Mrsa Np With Linezolidmentioning

confidence: 99%

European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid

Chastre

Blasi

Masterton

et al. 2014

Clinical Microbiology and Infection

View full text Add to dashboard Cite

Methicillin-resistant Staphylococcus aureus (MRSA) is an important cause of antimicrobial-resistant hospital-acquired infections worldwide and remains a public health priority in Europe. Nosocomial pneumonia (NP) involving MRSA often affects patients in intensive care units with substantial morbidity, mortality and associated costs. A guideline-based approach to empirical treatment with an antibacterial agent active against MRSA can improve the outcome of patients with MRSA NP, including those with ventilator-associated pneumonia. New methods may allow more rapid or sensitive diagnosis of NP or microbiological confirmation in patients with MRSA NP, allowing early de-escalation of treatment once the pathogen is known. In Europe, available antibacterial agents for the treatment of MRSA NP include the glycopeptides (vancomycin and teicoplanin) and linezolid (available as an intravenous or oral treatment). Vancomycin has remained a standard of care in many European hospitals; however, there is evidence that it may be a suboptimal therapeutic option in critically ill patients with NP because of concerns about its limited intrapulmonary penetration, increased nephrotoxicity with higher doses, as well as the emergence of resistant strains that may result in increased clinical failure. Linezolid has demonstrated high penetration into the epithelial lining fluid of patients with ventilator-associated pneumonia and shown statistically superior clinical efficacy versus vancomycin in the treatment of MRSA NP in a phase IV, randomized, controlled study. This review focuses on the disease burden and clinical management of MRSA NP, and the use of linezolid after more than 10 years of clinical experience.

show abstract

Section: Clinical Management Of Mrsa Np With Linezolidmentioning

confidence: 99%

European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid

Chastre

Blasi

Masterton

et al. 2014

Clinical Microbiology and Infection

View full text Add to dashboard Cite

show abstract

“…A vancomicina é eficiente no tratamento das infecções causadas pelas cepas MRSA, apesar de apresentar efeitos nefrotóxicos e ototó-xicos (25,35,43) . Novamente, o S. aureus ganhou a "batalha", pois em 1997 Hiramatsu, no Japão, descreveu uma cepa A resistência do S. aureus aos antibióticos tem sido desenvolvida por mutações em seus genes ou pela aquisição de genes de resistência de outras bactérias da mesma espécie (ou até de outras).…”

Section: Tabelaunclassified

Staphylococcus aureus: visitando uma cepa de importância hospitalar

Santos¹,

Santos²,

Freitas³

et al. 2007

J. Bras. Patol. Med. Lab.

178

View full text Add to dashboard Cite

O Staphylococcus aureus é uma bactéria do grupo dos cocos gram-positivos que faz parte da microbiota humana, mas que pode provocar doenças que vão desde uma infecção simples, como espinhas e furúnculos, até as mais graves, como pneumonia, meningite, endocardite, síndrome do choque tóxico e septicemia, entre outras. Essa bactéria foi uma das primeiras a serem controladas com a descoberta dos antibióticos, mas, devido a sua enorme capacidade de adaptação e resistência, tornou-se uma das espécies de maior importância no quadro das infecções hospitalares e comunitárias. Neste artigo faremos uma revisão sobre esse agente infeccioso e as bases dos mecanismos das patologias por ele provocadas, de forma a ressaltar a necessidade de mantê-lo como alvo para o desenho de novos antibióticos. IntroduçãoO Staphylococcus aureus é uma bactéria esférica, do grupo dos cocos gram-positivos, freqüentemente encontrada na pele e nas fossas nasais de pessoas saudáveis. Entretanto pode provocar doenças, que vão desde uma simples infecção (espinhas, furúnculos e celulites) até infecções graves (pneumonia, meningite, endocardite, síndrome do choque tóxico, septicemia e outras). A implantação da antimicrobianoterapia, no início da década de 1930, com o emprego da sulfanilamida (descoberta por Gerard Domagk em 1932),

show abstract

“…96 In some groups of severely ill patients, linezolid therapy has proved to be more effective than vancomycin. 97 Despite the cost, the drug can be highly effective, and the reduced length of hospital stay in comparison with vancomycin may make the drug a cost-effective choice in some subgroups of severely ill patients. 98,99 It may be an appropriate alternative to vancomycin in some patients with impaired renal function, poor venous access, or inability to tolerate glycopeptides.…”

Section: Antibiotic Treatment Of Community-acquired Mrsa Infectionsmentioning

confidence: 99%

Community-acquired methicillin-resistant Staphylococcus aureus

Elston

2007

Journal of the American Academy of Dermatology

169

134

View full text Add to dashboard Cite

Cost-effectiveness of linezolid versus vancomycin in mechanical ventilation-associated nosocomial pneumonia caused by methicillin-resistant staphylococcus aureus

Cited by 26 publications

References 39 publications

European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid

European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid

Staphylococcus aureus: visitando uma cepa de importância hospitalar

Community-acquired methicillin-resistant Staphylococcus aureus

Contact Info

Product

Resources

About